In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deal-Making Trends

2020 Could Spell The End Of Mega-Mergers, For Now

Industry experts expect a continued uptick in deals valued between $2bn-$10bn this year as buyers look to add critical mass in areas like oncology, rare disease and cell and gene therapy. Divestitures to free up capital and narrow focus should continue too.

Business Strategies Commercial Companies

The Only Way Is Nasdaq – Part One

The US Nasdaq exchange has become the only option for ambitious UK and European biotechs.

Business Strategies C-Suite Speaks Commercial

Investing In People: Aligning VCs And Today’s Entrepreneurs

In the latest instalment of our VC playbook series, In Vivo sits down with Roel Bulthuis, managing partner at INKEF Capital, to discuss the group’s approach to health care investing in Europe, the importance of funding a team not just a project and how life sciences venture capital is evolving with the emergence of health tech.

Business Strategies C-Suite Speaks Commercial

Creating Stability In A Time Of Transition

UK-centric investment firm Syncona’s model of “founding, building and funding” early-stage biotech companies – with a commitment to the longer term – hopes to help make Great Britain a cell and gene therapy powerhouse.

Leadership Financing Gene Therapy

Deals

Latest From Deals

Dealmaking Quarterly Statistics, Q1 2021

During Q1, biopharma merger and acquisition value reached $34.8bn and drew in $35bn in potential deal value (PDV) from alliances. Device company M&A values reached $10.2bn, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $5bn.

Deals Market Intelligence

Financing Quarterly Statistics, Q1 2021

To open the year, biopharmas brought in an aggregate $33.2bn in financing and device company fundraising totaled $2.8bn; while in vitro diagnostic firms and research tools players raised $7bn ($6.1bn).

Deals BioPharmaceutical

Deals In Depth: March 2021

BridgeBio Pharma’s affiliate QED Therapeutics granted and Helsinn Group exclusive global rights (excluding Greater China) to the FGFR1-3 inhibitor infigratinib in oncology and all other indications except skeletal dysplasias (including achondroplasia). BridgeBio could see up to $2.45bn in payments from the deal, including over $100m in up-front, regulatory, and launch payments, and the remainder in sales milestones. In the month’s top M&A, Amgen entered into an agreement to acquire fellow public biotech Five Prime Therapeutics for about $1.9bn, gaining Phase III-ready bemarituzumab for frontline advanced gastric or gastroesophageal junction cancer.  

Deals Market Intelligence

Pharma-Biotech Licensing Trends To Watch For In 2021

More option deals, greater use of alternative remedy clauses and aggressive diligence of assets. Geoffrey Spolyar, special counsel at Cooley, spotlights some of the changes he is seeing in pharma and biotech partnership agreements and explains why these trends matter in 2021.

Business Strategies Commercial

Deals Shaping The Medical Industry, March 2021

Derived from Biomedtracker, the Deal-Making column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in March 2021. Data provided by Biomedtracker.

Commercial Companies

Deals In Depth: February 2021

Molecular Templates penned a research collaboration with Bristol Myers Squibb to discover and develop multiple therapies designed for specific oncology targets using Molecular’s next-generation engineered toxin body platform. BMS paid $70m up front and could shell out development and regulatory milestones up to $874.5m and $450m upon the achievement of certain sales milestones. ICON entered into a definitive agreement to acquire fellow public CRO PRA Health Sciences in a 48% cash and 52% stock transaction valued at approximately $12bn. Financing reached $11.4bn in biopharma, $1.2bn in device, and $1.5bn in diagnostics.

Deals Market Intelligence
UsernamePublicRestriction

Register